

Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients with Submental Fullness due to Submental Fat: A Postmarketing Surveillance Study in Korea

First published: 30/08/2018

Last updated: 22/04/2026

Study

Finalised

Administrative details

EU PAS number

EUPAS23762

Study ID

25581

DARWIN EU® study

No

Study countries

 Korea, Republic of

Study description

This study is a prospective, observational postmarketing surveillance (PMS) conducted under the requirements of the Korean Ministry of Food and Drug Safety (MFDS) to evaluate the safety and effectiveness of BELKYRA Inj. in routine clinical settings when administered to patients in Korea for the improvement of moderate to severe convexity or fullness associated with SMF in adults.

Study status

Finalised

Research institutions and networks

Institutions

DreamCIS

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Suzanne St Rose CT.Disclosures@abbvie.com

Study contact

CT.Disclosures@abbvie.com

Primary lead investigator

Suzanne St Rose

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 30/04/2018

Actual: 15/12/2017

Study start date

Planned: 30/09/2018

Actual: 07/09/2018

Date of final study report

Planned: 30/11/2023

Actual: 23/09/2020

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

AbbVie

Study protocol

[CMO-EPI-FAS-0537_FINAL_V1.0_20170929_ENG_clean_Redacted.pdf](#) (886.25 KB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Non-EU RMP only

Other study registration identification numbers and links

CMO-EPI-FAS-0537

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Effectiveness study (incl. comparative)

Safety study (incl. comparative)

Data collection methods:

Primary data collection

Main study objective:

1. To assess the safety profile of BELKYRA routine Inj. in routine clinical practice in adult patients treated for SM fullness due to SMF
2. To assess the effectiveness of BELKYRA Inj. in routine clinical practice in adult patients treated for SM fullness due to SMF.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medicinal product name, other

Belkyra

Anatomical Therapeutic Chemical (ATC) code

(D11AX24) deoxycholic acid

deoxycholic acid

Medical condition to be studied

Fat tissue increased

Population studied

Short description of the study population

This study will include adult patients (≥ 18 years of age) in South Korea treated with BELKYRA Inj. for the improvement of moderate to severe convexity or

fullness associated with SMF in adults according to the approved label.

Age groups

- Adults (18 to < 46 years)
 - Adults (46 to < 65 years)
 - Adults (65 to < 75 years)
 - Adults (75 to < 85 years)
 - Adults (85 years and over)
-

Estimated number of subjects

600

Study design details

Setting

BELKYRA Inj. is expected to be mainly used at clinics (specializing in dermatology, plastic surgery, and aesthetic medicine), university hospitals, and general hospitals with dermatology, plastic surgery, or aesthetic medicine departments; therefore, surveillance will be mainly conducted by collecting relevant information on treated patients from contracted clinicians at these locations.

Outcomes

All adverse events that occur during and/or after administration of BELKYRA injection treatment throughout the follow-up period, Investigators' and patients' rating of improvement of fullness associated with submental fat, during follow-up using validated scales.

Data analysis plan

- Full analysis set - patients whose case report form were retrieved: the demographic data, baseline characteristics including diagnosis, treatment history, concurrent disease, etc. and concomitant medications
- Safety analysis set- patients who received an initial BELKYRA Inj. treatment, completed the Follow-up/Exit Visits (non-treatment) within 3 months of the last BELKYRA Inj. treatment for safety information (via in-office visit or telephone) with case report forms retrieved
- Effectiveness analysis- patients who received an initial BELKYRA Inj. treatment and have been evaluated for effectiveness of BELKYRA Inj. for the treatment of excess SMF by the investigator or by the patient.

Documents

Abstract of study report

[CMO-EPI-FAS-0537_Summary_Redacted.pdf](#) (206.67 KB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s), other

Data sources (types)

Other

Data sources (types), other

Prospective patient-based data collection

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No